Recent developments in targeting protein misfolding diseases  by Denny, Rajiah Aldrin et al.
Bioorganic & Medicinal Chemistry Letters 23 (2013) 1935–1944Contents lists available at SciVerse ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclBMCL DigestRecent developments in targeting protein misfolding diseases0960-894X  2013 Elsevier Ltd.
http://dx.doi.org/10.1016/j.bmcl.2013.01.089
⇑ Corresponding author.
E-mail address: lori.gavrin@pﬁzer.com (L.K. Gavrin).
Table 1
Diseases and targets associated with loss of function
LOF disease LOF protein
Cystic ﬁbrosis CFTR
Gaucher’s disease Glucocerebros
Hypogonadotropic hypogonadism GNRH
Nephrogenic diabetes insipidus V2R
COPD, emphesyma A1AT
Fabry disease Alpha-galacto
Retinitis pigmentosa Rhodopsin
Open access under CC BY-NC-ND license.Rajiah Aldrin Denny, Lori Krim Gavrin ⇑, Eddine Saiah
BioTherapeutics Chemistry, Pﬁzer Worldwide Medicinal Chemistry, 200 CambridgePark Drive, Cambridge, MA 02140, United States
a r t i c l e i n f oArticle history:
Received 16 November 2012
Revised 18 January 2013
Accepted 21 January 2013
Available online 4 February 2013
Keywords:
Protein misfolding
Chaperone
Cystic ﬁbrosis
Gaucher disease
Toxic oligomer
Serum amyloid P (SAP)
Proteostasisa b s t r a c t
Protein misfolding is an emerging ﬁeld that crosses multiple therapeutic areas and causes many serious
diseases. As the biological pathways of protein misfolding become more clearly elucidated, small mole-
cule approaches in this arena are gaining increased attention. This manuscript will survey current small
molecules from the literature that are known to modulate misfolding, stabilization or proteostasis. Spe-
ciﬁcally, the following targets and approaches will be discussed: CFTR, glucocerebrosidase, modulation of
toxic oligomers, serum amyloid P (SAP) sections and HSF1 activators.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.idaseProtein folding is the process by which a protein attains a well
deﬁned three-dimensional structure known as its native state. This
tertiary structure is reached through the folding of the polypeptide
chain starting from a disordered state referred to as the unfolded
state. The unfolded protein has both high entropy and high free en-
ergy (see Fig. 1). The high entropy is due to the large number of
possible conformational states while the high free energy reﬂects
the protein instability. As the protein starts to fold, the free energy
decreases and the number of accessible conformational states de-
crease as well. The folded native conformation is reached when
the free energy is at a minimum, however local minima can trap
the protein in an intermediate state slowing the folding process.
Aggregation occurs when folding intermediates or partially folded
states expose hydrophobic amino acid residues or regions that are
largely buried in the native state. Aggregation is mainly driven by
hydrophobic forces and results in the formation of amorphous
aggregates, instable oligomers and ultimately amyloid ﬁbrils
(Fig. 2). These thermodynamically stable structures are accessible
to proteins under denaturing conditions and are also driven by
the protein sequence.
The cellular machinery has evolved a stringent quality control
system as part of the proteostasis network to ensure proper pro-
tein folding, trafﬁcking and degradation.1 However, despite the
exquisite proteostasis network control, a number of proteins still
fail to reach or maintain their native conformation leading to
protein misfolding. When unfolded or misfolded proteins cannotbe refolded by protein chaperones, they are targeted to the pro-
teasome or the lysosome for degradation. Several factors contrib-
ute to misfolding: somatic or genetic mutations, aging, changes
in the intracellular environment such as pH, temperature, oxida-
tive stress and metal ions. Protein misfolding is linked to a large
number of diseases, including cystic ﬁbrosis, Alzheimer’s disease,
Parkinson’s disease, and ALS (Lou Gehrig’s disease) and is
becoming increasingly more common as the population ages.
These diseases can be deﬁned and classiﬁed as ‘loss’ or ‘gain’
of protein function.2 Loss of function (LOF) occurs if the impro-
per folding results in the protein failing to achieve its functional
conformation or reach its required location in the cell. Examples
of diseases and targets associated with loss of function are
shown in Table 1.
Gain of function (GOF) occurs when a protein accumulates,
leading to toxic oligomers or aggregates that can adversely affect
cell function. Examples of diseases and targets associated with gain
of function are shown in Table 2.sidase
Figure 1. Schematic representation of protein folding energetics and how a pharmacological chaperone increases protein stability. For clarity purposes, the various protein
states (misfolded, unfolded, folded and folded in presence of a chaperone) are shown on the same energy landscape. The reader should note that some proteins fold co-
translationally while others are natively unfolded.
Figure 2. Folding intermediates leading to oligomer and amyloid formation.
Table 2
Diseases and targets associated with gain of function
GOF disease GOF protein
Alzheimer’s disease Amyloid beta, tau
Type II diabetes Amylin
Parkinson’s disease a-Synuclein
ALS (Lou Gehrig’s disease) SOD1
Huntington’s disease Huntingtin protein
Creutzfeldt-Jakob disease (mad cow) Prion protein
Familial amyloid polyneuropathy TTR
1936 R. A. Denny et al. / Bioorg. Med. Chem. Lett. 23 (2013) 1935–1944Drug discovery strategies that restore protein folding and func-
tion can be grouped into three different categories:
1. Stabilization of a speciﬁc misfolding-prone or mutant protein
using pharmacological chaperones. A small molecule pharma-
cological chaperone increases the population of the folded state
by direct binding and stabilization, thus pulling the protein
towards a lower free energy minimum (Fig. 1). Examples of
mutated proteins that can be stabilized by correctors or chaper-
ones include CFTR, glucocerebrosidase (activation or inhibition)
and rhodopsin mutations.
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that stabilizes the native state or the partially folded state and
prevents the formation of oligomers or amyloids (see Fig. 2).
Examples of aggregated proteins that could be inhibited at the
partially folded state include SOD1, prion proteins, and
lysozyme.
3. Enhancing proteostasis by modulating the biological capacity of
the cell’s quality control protein network. Small molecule prote-
ostasis regulators induce the unfolded protein response. This
leads to the coordinated up-regulation of natural chaperones
or the endoplasmic reticulum quality control capacity.
The chaperones, co-chaperones and folding enzymes can
reconstruct the folding free energy of mutant enzymes, ‘push-
ing’ more protein toward the native state by lowering the
energy of intermediate and transition states and thus minimiz-
ing misfolding. Examples of proteostasis targets include HSF1
(heat shock transcription factor 1), HSPs (heat shock proteins),
ubiquitin targeted proteins, and proteases. Examples of diseases
and targets associated with proteostasis are shown in Table 3.Table 3
Diseases and targets associated with proteostasis
Potential indication Proteostasis target
Huntington disease HSF1
Parkinson’s disease Hsp90
Neurodegenerative diseases Usp14
Lysosomal storage diseases Ryanodine receptor
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Figure 3. Structure of Kalydeco™, 1.Several reviews were published recently covering various topics
related to protein misfolding.3–7 In the present digest, we will focus
on recent developments within the 3 aforementioned strategies of
protein function restoration. Speciﬁcally, within strategy 1, correc-
tors of CFTR for the treatment of cystic ﬁbrosis and glucocerebro-
sidase chaperones for the treatment of Gaucher’s disease will be
highlighted. Novel approaches towards ameliorating the aggrega-
tion of misolded proteins will also be discussed in the toxic oligo-
mer and serum amyloid P (SAP) sections. Although, HSF1 is not the
only proteostasis target being pursued in this space, the large num-
ber of recent publications on the identiﬁcation of HSF1 activators
aimed at enhancing the proteostasis network makes it a suitable
topic of discussion in the present digest. Within the scope deﬁned
above, protein truncation and nonsense stop codons are considered
out of the mandate of this digest and are not discussed herein.
Cystic ﬁbrosis: CFTR correctors
Cystic ﬁbrosis (CF) is the most common lethal genetic disease
affecting Caucasians. Worldwide, approximately 70,000 people
suffer from this disease.8 CF is caused by mutations in the cystic
ﬁbrosis transmembrane conductance regulator (CFTR), a chloride
channel that regulates epithelial ion and water transport in multi-
ple organs, including the lung, pancreas, liver, and intestinal tract.
In the lung, the loss of CFTR mediated chloride and bicarbonate
secretion is believed to cause airway surface dehydration that
leads to thick, sticky mucus accumulation, infection, inﬂammation
and destruction of tissue. Lung disease is the primary cause of mor-
bidity and mortality for those with CF. There is a huge unmet med-
ical need to develop a curative treatment for CF patients since it is a
fatal disease with a current median survival age of 37 years.
More than 1900 mutations in the CFTR gene have been identi-
ﬁed and described, though many are extremely rare.9 CFTR muta-
tions have been grouped into 5 classes, based on the molecular
mechanisms leading to the CFTR protein malfunction. Class I muta-
tions contribute to the formation of proteins with incomplete
length and provide protein with complete loss of activity (i.e.,mutation: G542X). Class II mutations are those that lead to abnor-
mal maturation of the CFTR protein in the ER and Golgi apparatus.
The effect of these mutations is premature degradation, leading to
a loss of function, since CFTR does not reach the cell membrane.
Examples of class II LOF mutations are F508del, I507del, and
S549R. The gene product having mutations of class III is properly
synthesized, transported, and incorporated into the cell mem-
brane, but has decreased functional activity in its gating properties,
that is, mutation: G551D/S. Mutations of class IV cause abnormal-
ities in the structure of the transmembrane protein and therefore
reduce the conduction of the chloride channel (i.e., mutations
R117H, R334W). Lastly, mutations altering the stability of mRNA
represent class V CFTR gene mutations.9
Kalydeco™ (Ivacaftor or VX-770, 1, Fig. 3), was approved in Jan-
uary, 2012 as the ﬁrst disease modifying drug for patients with a
class III gating mutation, G551D/S.10 Although Kalydeco is not cor-
recting the folding or trafﬁcking, it rectiﬁes the gating defect of cell
surface (mutant) CFTR. Kalydeco is currently approved for 5% of
all CF patients.
The most prevalent mutation present in CFTR, accounting for
more than 90% of CF patients, is when at least one allele contains
a deletion of the phenylalanine at position 508.11 This is an exam-
ple of a class II mutation, where the protein does not make it to the
cell surface. F508del CFTR also has a gating defect in the small per-
centage of protein that does make it to the cell surface. Therefore,
any therapy correcting the trafﬁcking of F508del will likely need to
be combined with a potentiator.
CFTR is comprised of 1480 amino acids and is classiﬁed as an
ABC transporter. CFTR consists of ﬁve domains, two nucleotide
binding domains (NBD1 and NBD2), a regulatory domain (R), and
two membrane spanning domains (MSD1 and MSD2), See Figure 4.
Protein activity is regulated by cAMP-dependent protein kinase A
(PKA)12 and also by binding of two ATP molecules at the NBD1
and NBD2 dimer interface.
Designing a pharmacological chaperone for F508del CFTR would
be the most direct approach to modulate misfolding. Unfortu-
nately, structure based drug design (SBDD) for CFTR is challenging
due to lack of an X-ray crystal structure. The published CFTR
homology models are based on ATPases with low sequence simi-
larity and with no R domain.13–17 The R domain in CFTR does not
have resemblance to any known crystal structure.13
Although the F508del mutation is in NBD1, the crystal structure
of F508del NBD1 and wild type (WT) NBD1 show very little struc-
tural difference.20 However, it should be noted that the construct of
the crystallized human NBD1 contains two solubilizing mutations,
while the construct of the crystallized human F508del NBD1 con-
tains several mutations (in addition to F508), in order to increase
both solubility and stability.20 Additionally, the crystal structures
were obtained at 4 C, at which temperature there may be cold cor-
rection of protein. Further studies will be necessary to assess
whether these mutations could affect the structure of F508del
NBD1. Nevertheless, the structural similarity between WT NBD1
and F508del NBD1 hints at the kinetic nature of CFTR folding.
Any mutation that disrupts the folding mechanism by delaying
Figure 4. Homology model developed by Dalton et al.18 of CFTR with 7 prominent
mutations (described in the text) shown in CPK representation. MSD1, MSD2, NBD1
and NBD2 are highlighted in orange, blue, purple and green, respectively. The
F508del mutation is in NBD1. Figure was generated using Schrodinger’s Maestro
v9.3.19
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Figure 5. Structure of VX-809, 2.
1938 R. A. Denny et al. / Bioorg. Med. Chem. Lett. 23 (2013) 1935–1944the process of folding gets degraded by the endoplasmic reticulum
associated degradation (ERAD) pathways. Serohijos and team21
performed molecular dynamic simulations to identify meta-stable
intermediate states appearing on WT and mutant NBD1 folding
pathways. They observed that the NBD1 WT and mutant folding
pathways are populated differently and their kinetic accessibilities
of transitional intermediates are distinct, indicating the direct ef-
fect of the Phe508 deletion on NBD1 folding.21
For patients who have F508del CFTR, the only therapy currently
available is supportive care. However, it has been shown that
F508del CFTR is poised for repair and can be rescued by small mol-
ecules. There are several recent reviews on molecules that modu-
late CFTR and there is also a collection of CFTR modulators
available in the public domain.22–24 The mechanism of action of
these F508del ‘correctors’ is unknown, as most have been identi-
ﬁed through phenotypic screening.
There are currently two small molecule correctors in the clinic
for evaluation in CF patients with the F508 deletion. These com-
pounds rescue F508del CFTR from degradation and help transit it
to the cell surface. VX-80925 (2, Lumacaftor, Fig. 5), in combination
with Kalydeco, has been tested in homozygous and heterozygous
F508del CF patients. The complete ﬁndings from this trial are ex-
pected in 2013, but initial Phase IIa study results in homozygousF508del patients have recently been published.26 In addition to
VX-809, Vertex Pharmaceuticals has also initiated a Phase II clini-
cal trial with a second corrector, VX-661 (structure not yet
available).27
Gaucher disease: glucocerebrosidase pharmacological
chaperones
Lysosomal storage diseases (LSDs) encompass over 40 inherited
metabolic diseases that result from lysosomal dysfunction. The
dysfunction is a consequence of the deﬁciency of a single enzyme
required for the metabolism and of substrates such as glycolipids,
glycans, polysaccharides and cholesterol. LSDs are classiﬁed based
on the kind of substrate that accumulates.28 Each LSD disorder re-
sults from different enzyme deﬁciencies. Gaucher disease (GD) is
caused by the accumulation of glycolipids called glucosylcera-
mides. The function of glucocerebrosidase is to hydrolyze the
b-glycosidic linkage of glycosylceramide. Depending on the accu-
mulating organ, a broad spectrum of clinical manifestations can
be observed, including anemia, thrombocytopenia, bone disease
and massive liver and spleen enlargement. Moreover, in the neur-
onopathic forms, brain deterioration is observed.
There are three GD clinical types, based upon the presence and
progression of neurological disease manifestations. Type 1 disease
(GD1), also referred to as non-neuronopathic GD, lacks primary
central nervous system (CNS) involvement. Neuronopathic or
CNS forms of the disease include types 2 and 3, where type 2 (acute
neuronopathic) is characterized by infantile onset and rapid pro-
gression of neurological symptoms, and type 3 (chronic neurono-
pathic) is characterized by onset later in childhood and slower
progression.
GCase, Figure 6, is a 516 residue enzyme with more than 300
known mutations.30 Many of these mutations are shown to be be-
nign, allowing GCase to fold to its native state and function nor-
mally.31 A few missense GCase mutations either partially or
completely abolish catalytic activity.32 This occurs through the
reduction of GCase stability resulting in premature proteosomal
degradation.33 These missense mutations are N370S, L444P,
F213I, and G202R, as highlighted in Figure 6.34–36 Among these,
N370S is by far the most common mutation and is primarily asso-
ciated with GD1. The L444P allele is most frequently associated
with the neuronopathic variants.37
The most common treatment for GD1 is enzyme replacement
therapy (ERT), by infusion of exogenous enzymes to process accu-
mulated glycolipid substrates. It has been shown that when GCase
is infused intravenously at regular intervals, it can lead to success-
ful treatment of many of the systemic manifestations of the dis-
ease, and has greatly improved the quality of life for patients
with GD1. However, the inability of recombinant enzymes to cross
the blood–brain barrier prevents amelioration of the CNS associ-
ated symptoms in the neuronopathic forms (2 and 3) of GD.
The second treatment option for GD is substrate reduction ther-
apy (SRT). The concept of this therapy is to reduce the amount of
the natural substrate that GCase should be metabolizing in the
lysosome. The structure of the natural substrate, glucosylceramide,
3, is shown in Figure 7. Despite ERT and SRT successes in patients
Figure 6. Crystal structure of GCase; line ribbon representation with missense
mutations Gly202, Phe213, Asn370 and Leu444 represented in magenta stick. Red
sphere identiﬁes the catalytic binding pocket available in GCase. This ﬁgure was
generated with 2V3D coordinates using Discovery Studio 3.5.29
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Figure 7. Structure of glucosylceramide, 3.
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Figure 8. First generation of pharmacological chaperones, 4–7. (NB-DNJ = N-
butyldeoxynojirimycin; NN-DNJ = N-nonyl deoxynojirimycin; ND-DNJ = N-dodecyl
deoxynojirimycin).
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Figure 9. First non-iminosugars, 8–10, identiﬁed as pharmacological chaperones
for GCase.
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ronal forms of the disease.
A beneﬁt of applying the pharmacological chaperone approach
to GCase, is that chaperones have the potential to cross the
blood–brain barrier, providing an opportunity to treat additional
symptoms of the disease. Isofagomine, 4, (Fig. 8), a competitive
small molecule inhibitor of GCase, at sub-inhibitory concentrations,
has been shown to act as a pharmacological chaperone leading to
increased catalytic activity.38 The major effect of isofagomine is to
facilitate the folding of newly synthesized GCase in the ER, thereby
increasing the lysosomal concentration of the enzyme.
The ﬁrst generation of GCase pharmacological chaperones
including isofagomine (4), NB-DNJ (5), NN-DNJ (6) and ND-DNJ
(7) are natural and alkylated iminosugars, which are inhibitors of
GCase, (Fig. 8).37 These iminosugars resemble the structure of the
natural glycoside substrate for GCase. Therefore, it is not surprising
that these compounds have high afﬁnity for the catalytic pocket of
glucosidases and poor isoenzyme selectivity. Although these com-
pounds promoted GCase trafﬁcking, they prevented its enzymatic
activity in the lysosome due to the fact that they are also potentGCase inhibitors.37 It was found that there is a narrow therapeutic
window between improving translocation and inhibiting enzyme
activity.39 In fact, isofagomine was discontinued in phase II clinical
trials for failing to meet efﬁcacy expectations, even though almost
all of the patients enrolled experienced an increased level of GCase
in white blood cells.40
The lessons from ﬁrst generation chaperones suggest that an
ideal chaperone should have weak binding to mutant GCase in
the endoplasmic reticulum (where it is formed) and no inhibitory
effects in the lysosome (where it functions). This demands that
chaperoning activity at the ER should be a balance between folding
enhancement and GCase activity. Reports on imino-sugar deriva-
tives with a more varying chaperone-inhibitor balance have re-
cently been reported in the literature.41–52
Alternatively, it is possible that pharmacological chaperones
binding to an allosteric pocket of GCase may provide a therapeutic
advantage by increasing translocation to the lysosome without
hindering its function. From the structural perspective, non-gly-
comimetic small molecules also have the potential advantage of
increasing selectivity over the other glycosidases. The ﬁrst non-
glycomimetic chaperones were identiﬁed through the use of a
quantitative high throughput screen on a structurally diverse li-
brary consisting of 59,815 compounds.53 The primary screen was
aiming to identify binders to WT GCase using an enzymatic assay.
A subsequent follow up assay in patient cell-based ﬁbroblasts
expressing mutant GCase was used to distinguish those com-
pounds with chaperone activity. Three structurally distinct classes
of compounds, namely aminoquinolines, sulfonamides and tria-
zines (8–10 in Fig. 9), showed good potency and efﬁcacy. More
importantly, these compounds exhibited selectivity against a-glu-
cosidase, a-galactosidase and b-hexosaminidase. Mutant cells trea-
ted with 40 lM of 8 or 9 showed an increase in N370S mutant
GCase activity and enhanced lysosomal co-localization, indicating
chaperone activity.
Recently, an HTS screen was reported using enzyme homoge-
nates from the spleen of a patient with Gaucher disease with the
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Figure 10. GCase pharmacological chaperones, 11–13.
1940 R. A. Denny et al. / Bioorg. Med. Chem. Lett. 23 (2013) 1935–1944N370S/N370S genotype.54–58 Under these conditions, GCase is be-
lieved to be present in a ‘normal’ physiological environment bound
to the native activator saposin C and other co-factors. Using this as-
say, a library of 250,000 compounds was screened and novel acti-
vators of mutant GCase, 11–13, were identiﬁed, Figure 10.
Theactivity of theprimaryhitswas conﬁrmed in subsequent cell-
based assays using patient-derived ﬁbroblasts. Translocation exper-
iments using Gaucher ﬁbroblasts showed that these compounds
facilitated translocation of GCase to the lysosome and thus act as
chaperones. These compoundswere shown to binddirectly toGCase
using microscale thermophoresis (ﬂuorescence using an IR laser),
however the exact binding site of these compounds is not known.
Amyloidoses: targeting toxic oligomers
Until recently, it was believed that the gain of function (GOF)
toxicity in protein misfolding diseases was associated with the
accumulation of the amyloids or ﬁbrils formed by the misfolded
protein. The latest research however suggests that the oligomers,
and not the ﬁbrillar forms, are the most toxic species, both
in vitro and in vivo.59–63 Metastable oligomeric structures have
been observed in the preparations of amyloid-forming peptides
such as a-synuclein, tau, prion, TTR, SOD1, Ab, and many others.
When produced intracellularly, oligomers expose ﬂexible hydro-
phobic surfaces that might contribute to trapping vital proteins.Figure 11. Schematic representing the iWhen produced extracellularly, oligomers can cause potentially
toxic alterations of cell membranes.64 The binding of these oligo-
mers to a variety of cell-surface receptor signaling molecules has
been hypothesized to be the cause of the toxicity in protein mis-
folding diseases.65 Furthermore, it has been proposed that these
pre-ﬁbrillar aggregates may initiate a number of cellular signals
and responses that can become self-perpetuating, independent of
the initial protein misfolding event.66
As the ﬁeld moves toward the common consensus that it is the
oligomers (and not the aggregates) which cause the toxicity, the
approaches to tackling these disorders must adapt accordingly.
The methods and molecules that will be designed to remove aggre-
gates versus oligomers will inherently be very different.
One strategy is to look for molecules that bind to the soluble
oligomers in order to preclude them from interacting with cell sur-
face receptors. In other words, the target in a screen would be the
oligomeric species itself, as shown below in Figure 11.
Key to this strategy is to develop a method to generate stable
and soluble oligomers in vitro, though their preparation is not an
easy task. Despite the enormous importance of these molecules,
detailed knowledge regarding the structure of Ab oligomers and
the biological mechanism behind their toxicity have remained un-
clear. This knowledge gap can be partly ascribed to the difﬁculty of
preparing stable and well-deﬁned oligomeric Ab species. Oligo-
mers made using standard methods are heterogeneous and contain
a mixture of different Ab species (monomers, multimers, various
oligomers, protoﬁbrils, ﬁbrils, etc.), which makes them difﬁcult to
study.67,68 Additionally, the oligomers that are prepared are quite
unstable. Typically, oligomers prepared and puriﬁed using stan-
dard methods stay in solution for only a few hours.69 The prepara-
tion of stable and soluble oligomers is not an easy task. However,
scientists at Crossbeta Biosciences70 reported a method for synthe-
sizing 1–42 peptide (Ab) type oligomer, implicated in Alzheimer’s
disease (AD). The reported Ab oligomers were claimed to be stable
for weeks.71 The identiﬁcation of small molecules that bind to such
an oligomer and prevent their aggregation could be of considerable
therapeutic value.
Another method that is being investigated is to remove the
toxic oligomer via its conversion into a non-toxic aggregate. Incor-
poration of toxic oligomers into protective amyloid-like protein
inclusions has been observed to reduce toxicity in mammalian
cells and mouse models.72 Scientists at the Medical College of
Georgia have recently published work that HspB1 (also known as
heat shock protein 25) has an important role in protein aggregation
diseases. Using biochemical methods, light scattering, and micros-
copy methods, they have shown that HspB1 sequesters toxic Ab
oligomers and accelerates their conversion into non-toxic
aggregates.73
Narayan et al.74 recently described how the extracellular chap-
erone clusterin sequesters all of the different oligomeric forms ofdea of toxic oligomer sequestration.
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Figure 12. Structure of O4, 14.
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work has shown that the sequestration of disease-associated pro-
teins into insoluble protein inclusions reduces their cytotoxicity
and alleviates cellular dysfunction.
Similarly, the small molecule O4, 14, (Fig. 12), has been shown
to bind directly to the hydrophobic amino acid residues in Ab pep-
tides and stabilizes the self-assembly of the seeding-competent,
b-sheet-rich protoﬁbrils and ﬁbrils.75 Notably, the O4-mediated
acceleration of amyloid ﬁbril formation efﬁciently decreases the
concentration of small, toxic Ab oligomers in complex, heteroge-
neous aggregation reactions. This result supports the hypothesis
that toxic oligomers can be ﬁbrillized efﬁciently with the use of a
small molecule.
One of the key challenges is to be able to accurately describe the
structure and dynamics of the heterogeneous population of species
formed during amyloid aggregation. This step is essential in order
to determine which oligomeric species is responsible for causing
the disease. If the structure of the toxic molecule is elucidated, it
should be more straightforward to identify ways to prevent their
formation, enhance their removal or block their effects.76
To further complicate the oligomer hypothesis, it is possible
that oligomers do not exist as a single molecule, but instead are
only present as dynamic and heterogeneous oligomers.77 Further
research in this ﬁeld is required to fully elucidate the structures
of the toxic species in GOF misfolding diseases.
Amyloidoses: serum amyloid P (SAP) inhibition
Serum amyloid P (SAP) is a plasma glycoprotein that is a mem-
ber of the pentraxin family of proteins. SAP is synthesized in the
liver and consists of ﬁve non-covalently associated identical sub-
units that form a donut-like structure. SAP succumbed to X-rayFigure 13. Top view of decameric SAP X-ray crystal structure, shown using 2A3W
coordinates. Figure is generated using Discovery Studio 3.5.29crystallography which elucidated that the symmetric pentameric
disc is approximately 100 Å in diameter, 35 Å in depth, and con-
tains a 20 Å pore in the center, as shown in Figure 13.78 Each SAP
subunit consists of 204 amino acids in a single polypeptide chain
with a metal-binding site containing two calcium ions.
Although SAP is evolutionary-conserved in all vertebrates, the
function of circulating SAP is not well understood. SAP is best
known as a universal constituent of ﬁbril deposits that are found
in all amyloid diseases. SAP binds to apoptotic cells, double-
stranded DNA and chromatin in a calcium-dependent manner.79
Therefore, it has been hypothesized that SAP functions as a scav-
enging protein which is able to recognize nuclear cell debris re-
leased during apoptotic and necrotic cell death, masking them
from the immune system. More recent work suggests that SAP
facilitates phagocytosis of apoptotic bodies by macrophages, indi-
cating that it plays a role in innate immunity.80 However, SAP
knockout mice developed normally and have an average lifespan,
suggesting that SAP blockade may not be detrimental.81
Since there are many different proteins responsible for the clin-
ically signiﬁcant amyloidoses, a speciﬁc treatment for each GOF
disease would require a speciﬁc drug to target the pre-ﬁbrillar pro-
tein precursor for each different amyloidosis. On the other hand, all
amyloid deposits contain a SAP component. Therefore, SAP has be-
come a target for drug discovery and development. SAP can com-
prise up to 14% of the dry mass of any type of an amyloid.82 In
fact, researchers have taken advantage of SAP’s afﬁnity to amyloids
by developing a clinical diagnostic technique called SAP scintigra-
phy where radiolabelled SAP protein is injected into patients to lo-
cate areas of amyloid deposition.83,84
Although the speciﬁc interactions of SAP binding to amyloids are
not known, SAP is believed to encase ﬁbrils thus stabilizing them by
inhibiting their removal via normal scavenging mechanisms. Since
SAP alone is highly resistant to proteolytic cleavage, when bound
to amyloidﬁbrils, it in turnprotects the amyloid fromdegradation.85
Actually, layers of SAP have been observed on the surface of amyloid
ﬁbrils.86 SAP’s critical role in the prevention of amyloid removal
makes it a key contributor to the pathogenesis of all amyloid
diseases.
In order to disrupt the binding of SAP to amyloids, Roche, in col-
laboration with the Imperial College of Medicine in London, per-
formed an HTS searching for competitors of SAP binding to the
amyloid formed from Ab oligomers. From this work, Ro 63-8695,
15, a palindromic bis-D-proline compoundwas discovered, (Fig. 14).
Ro 63-8695, also known as CPHPC (abbreviation of (R)-1-
[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-
carboxylic acid), was found to prevent SAP from binding to amyloid
ﬁbrils both in vitro and in vivo.87 A crystal structure of the SAP–
CPHPC complex revealed a decamer in which 5 CPHPC molecules
crosslinked and dimerized 2 SAP pentamers. The coordinates ofN
N
O
O
O
O
OH
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Figure 14. Structure of Ro 63-8695, 15 and 2A3W crystal structure ligand, 16.
Figure 15. Five molecules of 16 crosslinking 2 SAP pentamers, pdb 2A3W, generated using Discovery Studio 3.5.29
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Figure 16. Structure of HSF1 activator, 17.
1942 R. A. Denny et al. / Bioorg. Med. Chem. Lett. 23 (2013) 1935–1944the SAP–CPHPC complex are not available in the public domain.
However, a co-crystal structure with a different multivalent SAP
inhibitor, 16, has been published, (Fig. 15).88
As anticipated, the SAP–CPHPC complex is perceived as abnor-
mal by the liver and is instantly cleared, leading to a profounddeple-
tion of SAP from circulation, continuing for as long as the drug is
administered.89 In mouse models of systemic amyloidosis, CPHPC
was found to dramatically decrease circulating levels of SAP. Per-
haps even more important, CPHPC was found to bind to SAP that
had already bound to amyloids, dissociating the SAP from the ﬁbrils,
and causing amyloid regression.87 For these reasons, this compound
was advanced to clinical trials to ‘knock out’ human SAP. This was
the ﬁrst example of a clinical trial aimed at using a small molecule
to deplete a speciﬁc plasma protein from circulation and tissues.
CPHPC has been investigated in the clinic for several GOF dis-
eases including AA amyloidosis, Amyloid light chain (AL) amyloido-
sis, hereditary TTR amyloidosis, apolipoprotein AI amyloidosis,
ﬁbrinogen A amyloidosis, gelsolin amyloidosis, lysozyme amyloi-
dosis and Alzheimers disease.87,89 CPHPC depleted circulating SAP
by more than 90% while the drug was administered, however most
of the SAP remained bound to amyloid ﬁbrils, even after months of
treatment.90 The reason for the lack of SAP dissolution could be due
to the fact that human SAP binds more avidly than mouse SAP.
Moreover, there is a continuous production of 50–100 mg of new
hSAP per day.91 CPHPC was found to be well tolerated by patients
and has been administered to more than 60 subjects for a total of
more than 50 patient years without any adverse effects. However,
since there was no evidence of amyloid regression, CPHPC has not
been approved as a single agent drug. Currently, CPHPC is being
evaluated in a clinical trial in combination with a fully humanized
mouse monoclonal anti-human SAP antibody.92,93
Proteostasis modulation: heat shock transcription factor 1
(HSF1)
HSF1 is the master transcriptional regulator that controls the
heat shock response (HSR). It maintains proteostasis and resistanceto cellular stress through the production of heat shock proteins
(HSPs). Selective activation of HSF1 with a small molecule induces
the entire protein chaperone network. Chaperone proteins work
synergistically in cells to combat protein aggregation, enabling
the body’s natural response to effectively reduce protein
misfolding.94,95
Pharmacological activation of HSF1 and transcriptional activa-
tion of genes encoding protein chaperones can be achieved by dif-
ferent mechanisms. HSF1 can be activated by molecules that cause
cell stress or alternatively, by molecules that inhibit the protein
chaperones. Small molecules that activate HSF1 by promoting pro-
tein misfolding or cellular stress are unlikely to be useful in the
chronic treatment of diseases, as these molecules ultimately pro-
mote cellular dysfunction and lead to cell death. Therefore, phar-
macological agents that speciﬁcally activate HSF1 without
triggering a cell death pathway will be required.
Neef et al.96 performed a high throughput screen using a
humanized yeast based assay and reported a pyrazole sulfonamide
compound 17, (Fig. 16). Compound 17 was shown to activate HSF1
in mammalian and ﬂy cells. It was also found to elevate protein
chaperone expression and ameliorate protein misfolding and cell
death in polyQ-expressing neuronal precursor cells. Moreover, 17
was able to protect against cytotoxicity in a ﬂy model.96 Though
the speciﬁc mechanisms by which compound 17 promotes HSF1
expression remain unclear, it has been proposed that it interacts
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Figure 18. Structures of HSF1 activators, 22–25.
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Figure 17. Structures of Celastrol, 18, and derivatives, 19–21.
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chaperonin complex.
Morimoto and co-workers97 performed a screen of bioactive
small molecules that activates human heat shock response and
identiﬁed celastrol, 18, and its derivatives, 19–21, as shown in
Figure 17. While many HSR activators show delayed kinetics of
induction, triterpenoids 18–21 induce HSF1 rapidly, with kinetics
similar to those observed for heat shock in normal cells. This rapid
induction of the heat shock response represents a new class of
HSF1 inducers. HSF1 activation by celastrol was shown to promote
molecular chaperone expression and increases viability upon lethal
heat shock in yeast and mammalian cells.98 Although the ability of
Celastrol to promote heat shock and antioxidant pathways has pro-
ven to be efﬁcacious in reducing protein aggregation and cytotox-
icity in models of ALS,99,100 Alzheimer’s disease,101 Huntington’s
disease102 and Parkinson’s disease103 the therapeutic potential of
celastrol is limited due to its inherent cytotoxicity.104–106
Zhang et al.107 from CytRx also identiﬁed several small molecule
ampliﬁers of the heat shock response pathway. They developed a
high content target based primary screen,108 and validated their
assay by conﬁrming a previously identiﬁed 3,4-dichloroisocou-
main, serine protease inhibitor109 as an enhancer of HSF1. The
screening campaign included 4000 compounds, including known
bioactive libraries such as LOPAC and the NIH clinical collection.
Three potent gedunin derivatives, 22–24, and a sapanone A deriv-
ative, 25, were discovered as HSF1 activators, (Fig. 18). They
showed these compounds rescued cells from cell death caused by
the potent and selective 26S proteasome inhibitor MG-132. Fur-
thermore, RNAi knockdown of HSF1 signiﬁcantly reversed the
cytoprotective effects, conﬁrming that these compounds have an
HSF1-dependent mechanism of action. HSF1 ampliﬁers 22–25
were also tested in two mammalian cell based models of Hunting-
ton’s disease (HD), and were found to improve survival.107
The promising space of protein misfolding presents exciting
drug discovery opportunities in a wide range of therapeutic areas.
Innovative screening technologies and improved understanding of
protein misfolding kinetics and thermodynamics are already pro-
viding novel ways of correcting misfolded proteins in LOF diseases,
as shown in the case of CFTR and GCase. Signiﬁcant progress is
being made to better understand the toxicity of misfolded oligo-
meric intermediates and amyloid formation. This knowledge will
likely pave the way to the development of novel therapeutics to
treat the many devastating diseases caused by GOF amyloidoses.
Finally, modulating protein misfolding by targeting the proteosta-sis network, such as activating HSF1, and shifting misfolded
proteins towards their native state holds promising therapeutic
potential. Although drug discovery applications in the ﬁeld of pro-
teostasis are still emerging, our growing understanding of these
targets may provide intriguing opportunities to tackle a large num-
ber of diseases caused by protein misfolding.
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